Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone as Adjunctive Therapy in Major Depressive Disorder
NCT05850689Phase 3Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of lumateperone in major depressive disorder (MDD), sponsored by Intra-Cellular Therapies. Started May 2023; status: recruiting.
02
Drugs
lumateperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05850689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850689.